Galmed Pharmaceuticals Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$1.56next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Planned Commercial Launch of CG-100 Device in Europe | 31 Dec 2026 |
| Anticipated Initiation of Aramchol PoC Phase 1b/2 Study in Parkinson's Disease | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Aramchol Meglumine Bioavailability (AM-001 Study) Annually500.0Target: 500% increase in bioavailability compared to Aramchol Free Acid 300mg
Accumulated Deficit Annually-210.8MTarget: Reduce net operating losses through strategic pipeline refocusing and asset acquisitions
Watch Items
- Acquisition of Colospan Ltd. and commercial launch of CG-100 Intraluminal Bypass DeviceTrigger: Closing of transaction in Q2 2026 and planned $6 million investment for H2 2026 European launchAction: Monitor integration progress, regulatory milestones, and initial sales performance in Germany, Austria, and Switzerland
- Aramchol Phase 1b/2 Proof-of-Concept Study in Parkinson's DiseaseTrigger: Initiation of clinical trials in H2 2026Action: Track regulatory advice, IND-enabling activities, and patient enrollment milestones
- Going Concern Risk and Capital SufficiencyTrigger: Working capital of $15.8 million as of December 31, 2025, with substantial doubt about ability to continue as a going concernAction: Evaluate equity financing flexibility under the Baby Shelf Rule and potential dilution from the YA II PN, LTD. share resale agreement
Research as of 20 Jun 2026